<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034604</url>
  </required_header>
  <id_info>
    <org_study_id>2013-02-043</org_study_id>
    <nct_id>NCT02034604</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate efficacy and safety of naftopidil in patient with
      neurogenic lower urinary tract dysfunction not caused by benign prostatic hyperplasia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in patients' symptom questionnaires</measure>
    <time_frame>from baseline to 8 weeks of treatment</time_frame>
    <description>international prostate symptom score (IPSS) change, except QOL domain scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in uroflow parameters</measure>
    <time_frame>from baseline to 8 weeks of treatment</time_frame>
    <description>maximal flow rate, mean flow rate, voided volume and Changes in uroflowmetry parameters : maximal flow rate,mean flow rate, voided volume and PVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of patients showed an improvement in IPSS total scores of more than 25%.</measure>
    <time_frame>from baseline to 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefit, Satisfaction, and Willingness to Continue (BSW) questions</measure>
    <time_frame>8 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of global response assessment for Korean, GRA-K</measure>
    <time_frame>8 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction question, TSQ</measure>
    <time_frame>8 weeks after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety evaluation : incidence and severity of adverse events</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in each domain scores of IPSS</measure>
    <time_frame>up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in number of urinary frequency, nocturia</measure>
    <time_frame>up to 8weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Neurogenic Lower Urinary Tract Dysfunction</condition>
  <arm_group>
    <arm_group_label>Naftopidil Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naftopidil medication patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamsulosin Goup</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamsulosin medication patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftofidil</intervention_name>
    <arm_group_label>Naftopidil Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <arm_group_label>Tamsulosin Goup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 20 years old and above (upper limit of age: 80 years old)

          2. patients diagnosed as neurogenic bladder due to cerebrovascular accident, parkinson
             disease, spinal cord lesion, diabetic neuropathy etc)

          3. a+b

               1. IPSS ≥ 12 and QoL ≥ 3

               2. Maximum Flow Rate &lt;15 mL/s (Voiding volume) ≥ 120mL)

          4. Ability and willingness to correctly complete the micturition diary and questionnaire

          5. Capable of understanding and having signed the informed consent form after full
             discussion of the research nature of the treatment and its risks and benefits

        Exclusion Criteria:

          1. In male aged 50 years old and above, bladder outlet obstruction (Bladder Outlet
             Obstruction Index(BOOI) ≥40)

          2. In female, Pelvic Organ Prolapse ICS stage; POP-Q stage ≥ 2

          3. In female, the history of anti-incontinence operation.

          4. Patients with cancer of any type including cancer of the prostate or bladder

          5. Patients with urethral stricture or bladder neck contracture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyu-Sung Lee, M.D., Ph.D.</last_name>
    <phone>82-2-3410-3554</phone>
    <email>keleedr@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyu-Sung Lee, M.D., Ph.D.</last_name>
      <phone>82-2-3410-3554</phone>
      <email>ksleedr@skku.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hyun Wook You, M.D.</last_name>
      <phone>82-2-3410-1268</phone>
      <email>khdoct29@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kyu-Sung Lee, Ph.D, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>KYU-SUNG LEE</investigator_full_name>
    <investigator_title>professor,MD,PhD</investigator_title>
  </responsible_party>
  <keyword>Naftopidil</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Naftopidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

